93
faculty disclosures
(MH053851 and MH072672). Dr. Morilak has re-
ceived research funding from H. Lundbeck A/S in
the past year, for work unrelated to the research pre-
sented in this symposium. David Morilak receives
grant support from the NIMH and the Department of
Defense, USA, and a research grant from Lundbeck
unrelated to the content of this presentation.
Muller, Ulrich:
Disclosure: Honoraria for consul-
tancy, speaking at and organising conferences and
travel expenses for attending and presenting at con-
ferences from Eli Lilly, Heptares, Janssen-Cilag,
Lundbeck, Shire and UCB Pharma.
Murray, Robin:
Disclosure: None
Nathan, Pradeep:
Disclosure: This study was funded
by GSK. PJN is a former employee of GSK. Prsadeep
Nathan is an employee of GlaxoSmithKline Pharma-
ceuticals and is involved in drug development for
CNS disorders. Paul Maruff is an employee of Cog-
state, a company that provides cognitive testing and
analysis services to academia and industry.
Nemeroff, Charles:
Disclosure: Charles B. Nemer-
off, M.D., Ph.D. Declaration of Financial/Propriety
Interest: 2011 – 2014; Monday, February 03, 2014;
Research/Grants: National Institutes of Health
(NIH); Consulting: Xhale, Takeda, SK Pharma,
Shire, Roche, Lilly, Allergan, Mitsubishi Tanabe
Pharma Development America, Taisho Pharmaceu-
tical Inc., Lundbeck; Stockholder: CeNeRx BioPhar-
ma, PharmaNeuroBoost, Revaax Pharma, Xhale,
Celgene, Seattle Genetics, Abbvie: Scientific Advi-
sory Boards: American Foundation for Suicide Pre-
vention (AFSP), CeNeRx BioPharma (2012), Nation-
al Alliance for Research on Schizophrenia and
Depression (NARSAD), Xhale, PharmaNeuroBoost
(2012), Anxiety Disorders Association of America
(ADAA), Skyland Trail; Board of Directors: AFSP,
NovaDel (2011), Skyland Trail, Gratitude America,
ADAA; Income sources or equity of $10,000 or
more: PharmaNeuroBoost, CeNeRx BioPharma,
NovaDel Pharma, Reevax Pharma, American Psy-
chiatric Publishing, Xhale; Patents: Method and de-
vices for transdermal delivery of lithium (US
6,375,990B1); Method of assessing antidepressant
drug therapy via transport inhibition of monoamine
neurotransmitters by ex vivo assay (US 7,148,
027B2); Speakers Bureau: None, Honoraria: Vari-
ous, Royalties: Various, Expert Witness: Various.
Neumeister, Alexander:
Disclosure: None
Nishi, Akinori:
Disclosure: None
Nishikawa, Toru:
Disclosure: None
Norton, William:
Disclosure: No financial conflicts
of interest.
Nurnberger, John:
Disclosure: None
Nutt, David:
Disclosure: I have no interests to de-
clare other than have been a consultant for GSK.
Okano, Hideyuki:
Disclosure: H. Okano is the scien-
tific consultant of San Bio, Inc; Eisai Co Ltd; and
Daiichi Sankyo Co Ltd.
Pantelis, Christos:
Disclosure: The studies were
funded by National Health and Medical Research
Council (NHMRC) of Australia and Australian Re-
search Council (ARC). Additional support was pro-
vided by University of Melbourne, Melbourne
Health, Jack Brockhoff Foundation, Ian Potter Foun-
dation, AE Rowden White Foundation, Ramaciotti
Foundation, Pratt Foundation, Woods Family Trust,
Rebecca L Cooper Medical Research Foundation,
Australian Computing & Communications Institute,
Wellcome Trust, NARSAD, Stanley Foundation. Prof
Christos Pantelis was supported by a NHMRC Se-
nior Principal Research Fellowship (ID: 628386),
NHMRC Program Grant (ID: 566529) and NARSAD
Distinguished Investigator Grant.
Pardon, Marie-Christine:
Disclosure: None
Pariante, Carmine:
Disclosure: Professor Pariante
has received research funding from companies in-
terested in the use of anti-inflammatories in psychi-
atric disorders, such as Janssen; this amounts to
approximately 5% of all of his research funding,
which comes predominantly from governmental
agencies and charities.
Park, Sohee:
Disclosure: None
Parsey, Ramin V.:
Disclosure: None
Perlis, Roy:
Disclosure: None
Petryshen, Tracey:
Disclosure: Research supported
by the NIMH, Stanley Medical Research Institute,
and Avis and Clifford Barrus Medical Foundation.
Phillips, Anthony G.:
Prof. Phillips is involved in
research grants and fundings from Panora Pharma-
ceuticals. He has received funds from Otsuka Phar-
maceuticals.
Pilc, Andrzej:
Disclosure:
Dr. Pilc receives research
support from the National Science Center and Lund-
beck Pharmaceutical Company.
Pletnikov, Mikhail:
Disclosure: None
Popoli, Maurizio:
Disclosure: None
Poulin, Marie-Josée:
Disclosure: None
Prickaerts, Jos:
Disclosure: None
Rantamäki, Tomi:
Disclosure: T.R. has received re-
search support from Orion Pharma, Hermo Pharma
and Ono Pharmaceuticals.
Raskind, Murray:
Disclosure: None
Reif, Andreas:
Disclosure: None
Reiner, Peter:
Disclosure: None
Reis, Margareta:
Disclosure: None
Riva, Marco Andrea:
Disclosure: M.A. Riva has re-
ceived honoraria or research support from Bristol-
Myers Squibb, Dainippon Sumitomo Pharma, Eli
Lilly, Servier and Sunovion.
Robbins, Trevor:
Disclosure: Research funded by
the Wellcome Trust, MRC and EU (IMAGEN proj-
ect). TWR discloses consultancy with Cambridge
Cognition, E. Lilly, Shire Pharmaceuticals, Teva,
